Maeta M, Koga S, Osaki Y, Kanayama H, Oda M, Murakami A, Hirooka Y
Gan No Rinsho. 1984 Jul;30(8):899-904.
To study the effectiveness of CDDP for hepatic cancer, intra-hepato-arterial administration of CDDP (0.8-1.0 mg/kg/week) combined with 5-FU (250 mg/body/day) was performed for 10 patients with primary or metastatic hepatic cancer. As the results, partial response was obtained in 6 of 8 evaluable patients. However, the adverse effect was very high rate; leucopenia, thrombocytopenia and vomiting (nausea) were observed in 9, 6 and 6 of 10 patients respectively. The dose limiting factor of CDDP was not a nephrotoxicity but a bone marrow depression in this series. Though a noticeable antitumor effect of this modality was obtained, some improvements should be applied to it to decrease the adverse effect.
为研究顺铂对肝癌的疗效，对10例原发性或转移性肝癌患者进行肝动脉内给予顺铂（0.8 - 1.0毫克/千克/周）联合5-氟尿嘧啶（250毫克/人/天）的治疗。结果，8例可评估患者中有6例获得部分缓解。然而，不良反应发生率非常高；10例患者中分别有9例、6例和6例出现白细胞减少、血小板减少和呕吐（恶心）。在本系列研究中，顺铂的剂量限制因素不是肾毒性而是骨髓抑制。尽管这种治疗方式取得了显著的抗肿瘤效果，但仍应进行一些改进以降低不良反应。
